Triomics secures $15 million in Series A funding to streamline cancer clinical trials matching through automation

Triomics, a generative AI startup, is revolutionizing the way cancer patients are matched with clinical trials, potentially saving lives and extending life expectancy. Despite the thousands of trials conducted in the United States each year, only a small percentage of eligible patients actually enroll in these investigations of new treatments.

Founded by former MIT biotech researcher Sarim Khan and AI scientist at Adobe Hrituraj Singh, Triomics uses advanced generative AI technology to extract data from electronic health records (EHR) in minutes, a process that would typically take hours for medical staff to manually review. This innovative approach significantly reduces the time it takes for doctors to match patients with appropriate clinical trials.

The company’s AI software, OncoLLM, is currently being used by six cancer centers and hospitals, with plans to double that number by the end of the year. Triomics recently secured a $15 million Series A funding round from Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator to further develop its platform and expand its customer base.

While Triomics is not the only player in the AI clinical trial matching space, it stands out for its focus on processing large datasets specifically for cancer centers. The company’s founders are confident in the potential of their technology to not only streamline the clinical trial matching process but also assist medical staff in various other use cases, such as preparing for patient visits and submitting cancer data to regulatory agencies.

With the support of investors and a growing customer base, Triomics is poised to make a significant impact in the field of oncology and improve the outcomes for cancer patients seeking access to cutting-edge treatments.